EVALUATE THE RESULTS OF PAPILLARY THYROID CANCER AT THE MILITARY INSTITUTE OF RADIATION AND ONCOLOGY

Ngọc Phúc Lê1, Xuân Hậu Nguyễn2,
1 Military institute of Radiation and Oncology
2 Hanoi Medical University Hospital

Main Article Content

Abstract

Objective: Evaluation of surgical results of papillary thyroid carcinoma patients treated at the Military Institute of Radiation and Oncology. Subjects and Methods: A retrospective descriptive study on 62 patients diagnosed with papillary thyroid carcinoma who underwent total thyroidectomy or lobectomy and isthmusectomy at the Military Institute of Radiation and Oncology from 01/2018 to 01/2021. Results: The average age is 48,5 ± 12,2 years old; the most common age was < 55 years old (77,4%). 95,2% female, female/male ratio is 19,7/1. Common symptoms are detected thyroid tumor through health check (46,8%) and palpable tumor of neck (27,4%). The time of admission from the first symptoms is mostly < 6 months. Tumor location is common in the right lobe (46,5%); average tumor size was 28 ± 16 mm. Total thyroidectomy accounted for 69,4%.100% of patients have central cervical lymph node dissection, central and lateral neck dissection accounted for 21%, The rate of lymph node metastasis is 66.1%. There were no cases of distant metastasis. In terms of stage, the disease is mainly seen in stage I, accounting for 82.3%. Common early postoperative complications were hoarseness (8.1%) and numbness of hands and feet (17.7%), both occurred in patients with total thyroidectomy and lateral cervical lymph node dissection. Conclusions: Surgery therapy is an effective treatment for papillary thyroid cancer. At the Military Institute of Radiology and Oncology, total thyroidectomy is predominant, however, the rate of lobectomy and isthmus surgery is increasing due to the early arrival of patients. Surgery is an effective treatment with few complications.

Article Details

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018. 68(6):394-424.
2. Ricardo V L, Robert Y.Osamura et al. WHO classification of tumours of endocrine organs: IARC; 2017.
3. Trần Văn Thông (2014), Đánh giá kết quả sớm phẫu thuật ung thư tuyến giáp tại bệnh viện Đại học Y Hà Nội. Luận văn tốt nghiệp thạc sỹ y học 2014. Trường Đại học Y Hà Nội.
4. Nguyễn Tiến Lãng (2008), “Đánh giá kết quả phẫu thuật cắt toàn bộ tuyến giáp phối hợp với I131 điều trị ung thư tuyến giáp thể biệt hóa” Luận văn tốt nghiệp BS CK II, Hà Nội, 66 – 92. 34.
5. Lê Văn Quảng. Nhận xét đặc điểm lâm sàng và các phương pháp điều trị ung thư tuyến giáp tại Bệnh viện K từ năm 1992-2000. Tạp Chí Y Học. 2002.323-326.
6. Nguyễn Xuân Phong. Nghiên cứu đặc điểm lâm sàng và một số xét nghiệm trong ung thư biểu mô tuyến giáp. 2011. Đại học Y Hà Nội
7. Hoàng Huy Hùng (2016), Đánh giá di căn hạch của ung thư biểu mô tuyến giáp, Luận văn tốt nghiệp BSNT, Trường Đại học Y Hà Nội, Hà Nội.
8. Podda M, Saba A, Porru F, Reccia I, Pisanu A. Follicular thyroid carcinoma: differences in clinical relevance between minimally invasive and widely invasive tumors. World journal of surgical oncology. 2015. 13(1):193.